Chance News 42: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
==Quotation== | ==Quotation== | ||
==Forsooth== | ==Forsooth== | ||
"The potential public health benefits are huge" according to Dr. Paul M. Ridker lead author of [http://content.nejm.org/cgi/content/full/NEJMoa0807646>] referring to Crestor, a statin drug used to lower the risk of heart disease. "It's a breakthrough study. It's a blockbuster. It's absolutely paradigm-shifting" says Dr. Steven E. Nissen of the Cleveland Clinic who was not involved in the two-year study which consisted of about 18,000 people randomly assigned either to Crestor or to a placebo. | |||
On the other hand, from Dr. Sidney M. Wolfe of Worst Pills, Best Pills, Crestor "can cause potentially serious kidney toxicity that is not seen with other cholesterol-lowering drugs, and it is the only drug of its type that caused rhabdomyolysis, a life-threatening adverse muscle reaction...there is no medical reason for you to be taking Crestor when there are three safer drugs on the market for reducing cardiovascular events." | |||
Submitted by Paul Alper | |||
==Item 1== | ==Item 1== | ||
Revision as of 15:31, 16 November 2008
Quotation
Forsooth
"The potential public health benefits are huge" according to Dr. Paul M. Ridker lead author of > referring to Crestor, a statin drug used to lower the risk of heart disease. "It's a breakthrough study. It's a blockbuster. It's absolutely paradigm-shifting" says Dr. Steven E. Nissen of the Cleveland Clinic who was not involved in the two-year study which consisted of about 18,000 people randomly assigned either to Crestor or to a placebo.
On the other hand, from Dr. Sidney M. Wolfe of Worst Pills, Best Pills, Crestor "can cause potentially serious kidney toxicity that is not seen with other cholesterol-lowering drugs, and it is the only drug of its type that caused rhabdomyolysis, a life-threatening adverse muscle reaction...there is no medical reason for you to be taking Crestor when there are three safer drugs on the market for reducing cardiovascular events."
Submitted by Paul Alper